Results with dacomitinib (pf-00299804), an irreversible pan-HER tyrosine kinase inhibitor, in a phase II cohort of patients with HER2-mutant or amplified lung cancers

作者： Mark G Kris , David Ross Camidge , Giuseppe Giaccone , Toyoaki Hida , Joseph O'Connell

DOI:

关键词: